Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

F Disrespectful Fiduciary Responsibility

Concerned under the existential dread that "The robots could take over" and take control of the job of writer as easily as they did to that of the cashier or comedian, I attempted to create an article via an AI algoritm, the result .... There has been a lot of talk in the...
According to published reports | May 6, 2021 |

Bringing Hope to People Living with Neurodegenerative Diseases

Alpha Cognition Inc. ( TSX-V.ACOG , OTCMKTS: ACOGF , Forum ) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases. Stockhouse Media’s Dave Jackson caught up recently with Company CE...
Dave Jackson | October 20, 2021 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients

Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19. Biopharmaceutical company Chimerix Inc....
Streetwise Reports | April 29, 2020 |

Three COVID-19 Patients Treated with PLX Cells

Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. In a March 30 research note, Dawson James Securities analyst Jason Kolbert reported that three high-risk COVID-19 pati...
Streetwise Reports | April 2, 2020 |

Buzz on the Bullboards: The End of Fossil Fuels?

(Image via PyroGenesis Canada Inc.) Fossil fuels seem to be trending “the way of the dinosaurs” from which they came, especially considering the recent developments behind PyroGenesis Canada Inc. ( TSX-V: PYR , Forum ) . The Montreal-based h...
Stockhouse Editorial | September 2, 2020 |

Leading logistics company emphasizes risk mitigation

Our next company is Mullen Group Ltd. (TSX:MTL) , one of North America’s largest logistics providers, housing a network of independently operated businesses. We spoke with Randy Mercer, Director of Risk Management, who detailed the compa...
Brieanna McCutcheon | March 8, 2024 |

ExoTherapy offers hope for treating acute spinal cord injuries

Suffering from traumatic injuries can leave a person with long-term damages and/or side effects that are hard to navigate long after the initial incident has passed. Our next company is a publicly traded bio-pharmaceutical company, working on the development of its ...
Brieanna McCutcheon | September 19, 2023 |

Help 9 cent GEN.T save lives with cancer screening

Friday, March 4, 2016 | www.tickertrax.com | Help 9 Cent GEN.T Save Lives with Cancer Screening By Danny Deadlock, TickerTrax Note : I have been working on this report all day (s...
Danny Deadlock | March 4, 2016 |

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |
1 2 3 4 5 6 7 8 9 10 ...